Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial. D'Alise AM, Willis J, Duzagac F, Hall MJ, et al. Nat Med 2026 Jan 16. doi: 10.1038/s41591-025-04182.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

D'Alise AM, Willis J, Duzagac F, Hall MJ, et al. Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial. Nat Med 2026 Jan 16. doi: 10.1038/s41591-025-04182.
PMID: 41545594